Open Access Subscription Access
Open Access Subscription Access
Importance and Utility of Vagina as a Route for Drug Delivery System
The purpose of this review article is to highlight the importance of vaginal drug delivery system. Several studies proven that vagina is an effective route for drug administration intended for local action as well as systemic action. This route offers many advantages due to its large permeation area, permeability to large molecular weight drugs, rich vascularization, avoidance of first pass metabolism and relatively low enzymatic activity. Through this route steroidal compounds, spermicidal agents are already delivered to obtain suitable therapeutics action for prolong period of time with minimal side effects. Recently the vaginal route has been investigated for peptide and protein drug delivery. In this review we focused on different aspects related to vaginal drug delivery systems along with their anatomy physiology and factors affecting drug absorption from the vaginal route.
Vagina, Intravaginal Route, Peptide and Protein Drug Delivery.
- Choudhury A., Das S., Kar M., A Review on Novelty and Potentiality of Vaginal Drug Delivery, International Journal of PharmaTech Research, Vol. 3, 2011, P- 1033-1044.
- Chien Y. W., Yu K., Vaginal delivery and absorption of drugs. Encyclopedia of Pharmaceutical Technology. Vol. 16. Marcel Dekker Inc.; 1997: P.153-185.
- Garg S., Vermani K, The scope and potential of vaginal drug delivery. Pharm Sci Technology Today, 2000, p. 359-364.
- N. Dobaria, R. Mashru and N. H. Vadia Vaginal drug delivery systems: A Review of Current Status , East and Central African Journal of Pharmaceutical Sciences Vol. 10 2007, p. 3-13.
- Ashok.V, Kumar R. M., Murali D. and Chatterjee A., A review on vaginal route as a systemic drug delivery, Critical Review in Pharmaceutical Sciences, Vol 1(1), 2012, p. 1-19.
- Vagina, The Free Histology Encyclopedia, Available at: http://www.ihcworld.com/histowiki/doku.php?id=vagina.
- Chein. Y. W.,"Novel Drug Delivery System" 2nd edition, p. 529-584.
- Robinson J. R., X. Absorption Enhancers. In Encyclopedia of Pharmaceutical Technology; J. Swarbrick and J.C. Boylan, Eds, Marcel Dekker, Inc. New York, vol 18, 1999, p. 1-27.
- Howard C. A., Loyd V. A., Jr. Nicholas G. P., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, 8th edition.
- Ansel H. C., Popovich NG, Allen LV. Pharmaceutical dosage forms and drug delivery, 6th ed. Malvern, P. A. Williams and Wilkins 1985, p. 424.
- Ansel H. C., Allen V., Jr. Nicholas G, Ansel's P., Pharmaceutical Dosage Forms and Drug Delivery Systems. 8th edition.
- Guyot M., Fawaz F. Present and future choices of vaginal drug dosage forms. Classical forms., J. Pharm Belg 1993, p. 393.
- Gad cox shayne',"Pharmaceutical Manufacturing Handbook", Vaginal Drug Delivery, p. 809-857.
- Fusun A., Gazi university, Faculty of Pharmacy, Department of1. Choudhury A., Das S., Kar M., A Review on Novelty and Potentiality of Vaginal Drug Delivery, International Journal of PharmaTech Research, Vol. 3, 2011, P- 1033-1044.
- Ahuja A., Khar R., Ali J. Mucoadhesive drug delivery systems. Drug Dev. Ind. Pharm., 1997, p. 489–415.
- Patel G. M. and Patel A. P., A novel effervescent bioadhesive vaginal tablet of ketoconazole: formulation and Invitro evaluation, International Journal of PharmTech Research Vol.2, No.1, p. 656-667.
- Bansal K., Pant P., Rao P. R. T., Padhee K, Sathapathy A., Prithipal Singh Kochhar, Development and Evaluation of Dienogest Vaginal Tablet for Treatment of Endometriosis, International Journal of Research in Pharmaceutical and Biomedical Sciences Vol. 2, 2011, p. 728-737.
- EL-Kamel A. S., Sokar M. S., Naggar V. F., Gamal S. S., Bioadhesive controlled release metronidazole vaginal tablets, Acta Pharm. 52 (2002) p. 171–179.
- Bhowmik B. B., Nayak B. S., Rout P. K. and Nayak U. K., formulation Development and Characterization of Metronidazole Microencapsulated Bioadhesive Gel for Vaginal Use, International Journal of PharmTech Research Vol.3, p. 209-219.
- Neves J. D., Bahia M. F., Gels as vaginal drug delivery systems, International Journal of PharmTech Research (2006) p. 1–14.
- Milica S., Vesna S., Valentina M., Development of Formulations for Vaginal gel carrier in the Pharmacy a Regulatory and Quality Aspect, Scientific Journal of the Faculty of Medicine in Niš 2012, 23-30.
- Yellanki S. K., Nerella N. K., Goranti S., Deb K. S., Development of Metronidazole Intravaginal gel for the treatment of bacterial vaginosis: Effect of Mucoadhesive Natural Polymers on the Release of Metronidazole, International Journal of PharmTech Research, Vol.2, No.3, July-Sept 2010, p. 1746-1750.
- Francois M., Snoeckx E., Putteman P., Wouters F., Proost D. E., Delaet J., A Mucoadhesive, Cyclodextrin-based Vaginal Cream Formulation of Itraconazole, January 16, 2003; Published: March 6, 2003, 1-5.
- USP Clindamycin Phosphate Vaginal Cream, for intravaginal use only not for ophthalmic. Dermal or oral use. Revised June 2008, p 1-11.
- Abass H., Kamel R., Abdelbary A., Metronidazole bioadhesive vaginal suppositories: formulation, in vitro and in vivo evaluation, International Journal of Pharmacy and Pharmaceutical Sciences, Vol 4, Issue 1, 2012, p. 344-355.
- European Pharmacopoeia 5.0, Veterinary liquid preparations for cutaneous application, p. 630-631.
- Gertrude-E. C., Hans A. R., Robert P., Eric E., and Roger D. C., Vaginal irritation models: The Current Status of Available Alternative and In Vitro Tests, 2011, p. 317-337.
- Robert P., Eric D., Gertrude-E. C., Hans A. R., Rodger D. C., Current status of available In vitro tests for vaginal irritation assessment, Institute for In vitro Science, Inc. (IIVS), Gaithersburg, MD, USA.
- Ayehunie S., Cannon C., LaRosa K., Pudney J., Anderson J. D. and Klausner M., Development of an in vitro alternative assay method for vaginal irritation. January 2011, p. 130–138.
- Esra B., Zeynep A. S., Sinem Y. K. and Andreas B. S., Strategies to Prolong the Intravaginal Residence Time of Drug Delivery Systems, J Pharmaceutical Science (www.cspsCanada.org) 2009, p. 312 – 336.
- Lee C.H., Anderson M. and Chein Y.W., The characterization of in-vitro spermicidal activity of chelating agent on human sperm, J. Pharm. Sci., 1996, p. 649-54.
- Gynecol O. J.,Van C. J., The in vitro activity of terconazole against yeasts: its topical long-acting therapeutic efficacy in experimental vaginal candidiasis in rats. Pub med 1991 Oct. p. 165.
- Chami F., Chami N., Bennis S., Trouillas J., Remmal A., Evaluation of carvacrol and eugenol as prophylaxis and treatment of vaginal candidiasis in an immunosuppressed rat model, Journal of Antimicrobial Chemotherapy (2004), p. 909–914.
- Osmond J. D., Douglas E., Fatih M. U., A Study of the Potential of the Pig as a Model for the Vaginal Irritancy of Benzalkonium Chloride in Comparison to the Nonirritant Microbicide PHI-443 and the Spermicide Vanadocene Dithiocarbamate, drug discovery program, department of reproductive biology, experimental pathology and virology. Paradigm Pharmaceuticals. Vol. 33, No. 4, 2005. p. 464-476.
- Manzer J. D., Akira K. ' Norman F.H. Ho , Jeffrey L. F. and William I. H., Topical vaginal drug delivery in the guinea pig. I. International Journal of PharmaTech Research 24 (1985) p. 209-218.
- Gupta A. K. Introduction to Pharmaceutics I-II CBS publishers and Distributers, 3rd edition, Darya Ganj, New Delhi India.
Abstract Views: 132
PDF Views: 2